ArticleEuropean heart journal open2026
Relationship of cancer and dual antiplatelet duration to long-term risk of ischaemic and bleeding outcomes after percutaneous coronary intervention.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Platelet-derived mitochondrial transfer in cancer metastasis: mechanisms, functional consequences, and translational opportunities.Clinical & experimental metastasis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: The long-term cardiovascular (CV) risks after percutaneous coronary intervention (PCI) in cancer patients are unclear. We assessed the risks of adverse events after PCI related to active or inactive cancer and the duration of dual antiplatelet therapy (DAPT). Methods and results: This is a retrospective cohort of all patients having PCI with second-generation drug-eluting stents in the national Veterans Affairs Healthcare System between 2008 and 2016. We compared patients with active cancer (cancer and chemotherapy/radiotherapy), inactive cancer (cancer without chemotherapy/radiotherapy), or no cancer using Cox proportional hazards regression models adjusted by the propensity for cancer. Models estimated hazard ratios (HR) and 95% confidence intervals (95% CI) for myocardial infarction (MI), major bleeding, and death and the relationship to duration of DAPT after PCI. Of 40 677 patients, 791 (2%) had active cancer, 7633 (19%) had inactive cancer, and 32 253 (79%) had no cancer. Over a mean 5.4 (SD 2.8) years, the risks of MI and major bleeding were higher in patients with active cancer (MI: HR = 1.18, 95% CI = 1.00, 1.40; major bleed: HR = 1.73, 95% CI = 1.43, 2.10) and inactive cancer (MI: HR = 1.13 95% CI = 1.07, 1.20; major bleed: HR = 1.30, 95% CI = 1.21, 1.41). Discontinuing DAPT more than 9 months after PCI associated with lower risks of MI (active cancer: HR = 0.91, 95% CI = 0.70, 1.19; inactive cancer: HR = 0.78, 95% CI = 0.70, 0.88) and major bleeding (active cancer: HR = 0.68, 95% CI = 0.49, 0.97; inactive cancer: HR = 0.87, 95% CI = 0.76, 0.99). Conclusion: Patients with cancer have higher risks of ischaemic and bleeding outcomes after PCI. However, we found no evidence that DAPT duration should differ from current guidelines in patients with cancer after PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.